Did You Know...
...In 1790, the cost to obtain a patent was between $4 and $5.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120082723 | Easily administrable solid preparation It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable preparation that does not affect dissolution property. The aforementioned object... | 04/05/2012 |
| 20120070497 | USE OF BOSWELLIC ACIDS FOR THE PROPHYLAXIS AND/OR TREATMENT OF DAMAGE TO AND/OR INFLAMMATION OF THE ISLETS OF LANGERHANS Disclosed are methods and compositions related to the use of boswellic acids (such as acetyl-11-keto-β-boswellic acid, 11-keto-β-boswellic acid, β-boswellic acid, acetyl-β-boswellic acid, 9,11-dehydro-β-boswellic acid, acetyl-9,11-dehydro-β-boswellic acid, α-bosw... | 03/22/2012 |
| 20110305759 | COMPOSITION COMPRISING CALCIUM CARBONATE AS A WHITE PIGMENT A white colouring composition comprising calcium carbonate as a white pigment. It may be used in the manufacture of food and pharmaceutical products.... | 12/15/2011 |
| 20110274753 | DUAL RELEASE ORAL TABLET COMPOSITIONS OF DEXLANSOPRAZOLE Dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.... | 11/10/2011 |
| 20110244041 | PLANT EXTRACT HYDROLYSATES AND ANTIBACTERIAL PRODUCT CONTAINING THE SAME The invention relates to a hydrolyzate from at least one extract of at least one plant material selected from the group consisting of at least one genus: Equiseti, Juglandis, Millefolii, Quercus, Taraxaci, Althaeae, Matricariae, Centaurium, Levisticum, Rosmarinus, An... | 10/06/2011 |
| 20110195102 | PEPTIDES USEFUL IN THE TREATMENT AND/OR CARE OF SKIN, MUCOUS MEMBRANES, SCALP AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Peptides with general formula (I): R1-AA1-AA2-AA3-AA4-R2 its stereoisomers, mixtures thereof, and its cosmetically or pharmaceutically acceptable saits, a method of preparation, cosmetic or pharmaceutical... | 08/11/2011 |
| 20110150992 | QUININE FORMULATIONS, METHOD OF MAKING, AND METHOD OF USE THEREOF Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or n... | 06/23/2011 |
| 20110111026 | HUMIDITY-RESISTANT DRUG FORMULATIONS AND METHODS OF PREPARATION THEREOF The invention relates to a pharmaceutical composition of a humidity-sensitive core comprising an active ingredient or pharmaceutically acceptable salt thereof; a coating over the core, the coating containing a cationic polymer; and an additional coating over the cationi... | 05/12/2011 |
| 20110097401 | METHODS FOR TREATING GASTROINTESTINAL DISORDERS Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus.... | 04/28/2011 |
| 20110033526 | PHARMACEUTICAL COMPOSITION OF ANTIBIOTICS AND PREBIOTICS FOR PREVENTING AND TREATING DYSBIOSIS DURING ANTIBACTERIAL THERAPY The invention relates to medicine and pharmacology, in particular to pharmaceutical compositions containing the following antimicrobial preparations: antibiotics and sulphanylamides combined with prebiotic in the form of a lactulose. The composition is used for preventi... | 02/10/2011 |
| 20110014286 | MIXTURE FOR PRODUCING RAPIDLY DISINTEGRATING TABLETS An isomalt-containing mixture including a) 60-97% by weight of agglomerated isomalt, b) 1-25% by weight of crosslinked polyvinylpyrrolidone, c) 0.1-15% by weight of lubricant, d) 1-15% by weight of water-insoluble, film-forming polymers, e) 0-15% by weight of water-solu... | 01/20/2011 |
| 20110008409 | PHARMACEUTICAL PREPARATION CONTAINING A GESTAGEN, AND KIT AND METHOD FOR TREATING ENDOMETRIOSIS USING THE PREPARATION The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that required to inhibit ovulation toget... | 01/13/2011 |
| 20100330179 | Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmac... | 12/30/2010 |
| 20100323013 | HYDROLYSATES MADE OF PLANT EXTRACTS AND ANTIBACTERIAL AGENT CONTAINING THE SAME The present invention relates to an antibacterial agent and a hydrolysate made of at least one extract that has been produced by extraction using ethanol/water from dried plant material of: a) at least one of the plants selected from the group consisting of: Verbena ... | 12/23/2010 |
| 20100297230 | COMPOSITIONS AND METHODS FOR PROSTATE AND MENSTRUAL/MENOPAUSAL RELATED HEALTH The disclosure provides compositions and methods and maintaining prostate health and relieving menstrual and menopausal related symptoms. The compositions comprise at least two of an icariin component, a quercetin component, a Maca component, a cocoa polyphenols compone... | 11/25/2010 |
| 20100247587 | PIGMENTATION-REGULATING COMPOUNDS The present invention relates to compounds of general formula (I): wherein X is selected from the group consisting of O or S and R is a linear or branched, saturated or unsaturated aliphatic group with from 2... | 09/30/2010 |
| 20100239664 | FORMS OF RIFAXIMIN AND USES THEREOF The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.... | 09/23/2010 |
| 20100183712 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS The present invention relates to acylated indanyl amines according to the general formula (I)
| |
| 20100183718 | COMPOSITIONS AND TREATMENT OF HEART DEFICIENCY IN NON-HUMAN ANIMALS The invention relates to novel compositions including an aldosterone antagonist and administered according to a predetermined dosage for treating heart deficiency in non-human mammals.... | 07/22/2010 |
| 20100151024 | THERAPEUTIC AGENT FOR ULCERATIVE COLITIS A method for treating a patient having ulcerative colitis, by administering a drug which containing an effective amount of tetracyclines is provided. The drug may also contain penicillins and/or metronidazoles.... | 06/17/2010 |
| 20100112056 | IMMEDIATE RELEASE DOSAGE FORMS OF SODIUM OXYBATE The present invention provides a pharmaceutical composition, presented as a solid unit dosage form adapted for oral administration of sodium oxybate. The preferred unit dosage form is a tablet comprising a relatively high weight-percentage of sodium oxybate, in combinat... | 05/06/2010 |
| 20100047349 | Stabilized solid preparation A stabilized solid preparation having stabilized drug content and stabilized appearance, comprising a main ingredient layer and a coating layer formed on the main ingredient layer, wherein the main ingredient layer comprises a granule or a fine particle comprising a sub... | 02/25/2010 |
| 20090317462 | PEPTIDE PHARMACEUTICAL FOR ORAL DELIVERY Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or ... | 12/24/2009 |
| 20090291138 | FILM-COATED PREPARATION HAVING IMPROVED STABILITY A film-coated preparation having excellent storage stability, which contains a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof, having a film layer containing one or more film coating base agents selected from polyvinyl alcoh... | 11/26/2009 |
| 20090208576 | Orally Disintegrating Tablets The present invention describes a directly compressible composite prepared by co-processing a water-soluble excipient and calcium silicate. The present invention further describes the incorporation of the co-processed composite into a tablet formulation. The orally disi... | 08/20/2009 |
| 20090196925 | NATURAL PRODUCT COATING FOR TABLETS An all-natural tablet coating composition comprised entirely of Certified Organic ingredients and organic compliant ingredients which can be applied to a compressed tablet core using conventional film coating techniques is provided. The coating is useful for preparing o... | 08/06/2009 |
| 20090175940 | Solubilized ibuprofen A process for producing a solubilized ibuprofen, preferably in the form of a granulate, the process comprising the steps of: providing a mixture comprising solid ibuprofen and a first base selected from the group consisting of sodium hydroxide, potassium hydroxide, sodi... | 07/09/2009 |
| 20090130210 | PHARMACEUTICAL COMPOSITIONS OF SIROLIMUS A pharmaceutical composition of sirolimus comprising an inert core and a sugar overcoat, wherein said sugar overcoat comprises sirolimus, a poloxamer other than poloxamer 188, microcrystalline cellulose and binder has been developed.... | 05/21/2009 |
| 20090130201 | polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-di... | 05/21/2009 |
| 20090123542 | PRIMARY COMPOSITION COMPRISING A LIPOPHILIC BIOACTIVE COMPOUND The invention relates to a primary composition in which at least one lipophilic bioactive compound is mixed with a whey protein, present in an amount effective to increase the bioavailability of the lipophilic bioactive compound. The invention also relates to an oral co... | 05/14/2009 |
| 20090117184 | Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception Gestagens, preferably dienogest, chlormadinone acetate or levonorgestrel, in combination with estrogens, for example ethinylestradiol, 17β-estradiol or estradiol valerate, and one or more pharmaceutically acceptable auxiliary agents/excipients provide lactose-free oral... | 05/07/2009 |
| 20090068268 | MELT GRANULATION OF A COMPOSITION CONTAINING A CALCIUM-CONTAINING COMPOUND A novel method for the preparation of a tablet comprising a calcium-containing compound, the method involves a melt granulation process by which a sugar alcohol is melted and embeds the calcium-containing compound so that a sufficient taste masking of the chalkiness is ... | 03/12/2009 |
| 20090060997 | PROCESS FOR PRODUCING A PHARMACEUTICAL PREPARATION FOR THERAPEUTIC TREATMENT OF ENDOMETRIOSIS CONTAINING A COMBINATION OF A GESTAGEN AND (6S)-5-METHYLTETRAHYDROFOLATE A combination of an anti-androgenic gestagen at a daily dose of from an ovulation-inhibiting dose up to at most twice the ovulation-inhibiting dose and from 0.1 to 10 mg of (6S)-5-methyltetrahydrofolate are used to produce a pharmaceutical preparation for therapeuticall... | 03/05/2009 |
| 20090049935 | Stabilized milnacipran formulation It is intended to provide a milnacipran formulation which is more stable than a conventionally known milnacipran formulation, and a method of stabilizing a milnacipran formulation. The object could be achieved by using a milnacipran-containing composition in which milna... | 02/26/2009 |
| 20080213348 | Agents for gene therapy of cerebrovascular disorders The present invention provides novel methods for treating cerebrovascular disorders, in which HGF is overexpressed by introducing an HGF gene. The methods of this invention using an HGF gene enable active treatment of cerebrovascular disorders, such as cerebral infarcti... | 09/04/2008 |
| 20080193522 | Use of Polymer Mixtures For the Production of Coated Pharmaceutical Formulations and Pharmaceutical Formulation With Mixed Polymeric Coating The invention relates to the use of mixture of 2 to 60 wt. % of one or more polymers (I) with 40 to 98 wt. % of one or more polymers (II), whereby the polymer (I) is a (meth)acrylate copolymer, containing 90 to 100 wt. % radically polymerised of 40 to 95 wt. % of C... | 08/14/2008 |
| 20080193533 | Sugar-Coated Agent A sugar-coated agent that includes a core, a film layer that mainly includes a film component, the outer surface of the core being coated with the film layer, a sugar coating layer that mainly includes a sugar coating component, the outside of the film layer being coate... | 08/14/2008 |
| 20080159987 | Use of Rifaximin for the Treatment of Restless Legs Syndrome Restless legs syndrome (RLS) is characterized by an urge for leg movement, often with abnormal leg sensations. Symptoms are triggered by rest, often at night, and improve temporarily with movement, especially walking. This syndrome has a prevalence ranging from 7% to 15... | 07/03/2008 |
| 20080095840 | Nifedipine controlled release compositions and preparation methods therefor A nifedipine controlled release composition is provided comprising a drug-layer and a push-layer at a ratio of 1:0.5˜3 by weight. The drug-layer contains nifedipine and 40˜99 percent by weight of the drug-layer of hydrophilic polyvinylpyrrolidone homopolymer and/or co... | 04/24/2008 |
| 20080020042 | Dosage form of sodium ibuprofen A non effervescent tablet of ibuprofen, comprising a tablet core and, if desired, a sugar or film coat, wherein the tablet core, based on the weight of the tablet core, consists of 50 to 100% by weight sodium ibuprofen hydrate and 50 to 0% by weight auxiliary material c... | 01/24/2008 |
